Services

Inquiry and ordering

Name*
Phone*
Email*
Product*
Content*

Aptamer-Drug Conjugate (ApDC) Development Services

Aptamer-drug conjugates (ApDCs) have emerged as a highly promising new strategy for the development of targeted small-molecule drugs due to their low molecular weight, good tissue permeability, high specificity, ease of synthesis and modification, and low immunogenicity; they are also a major research focus in the field of precision cancer therapy. Aptamer-drug conjugates (ApDCs) are designed to precisely deliver highly cytotoxic drugs to cancer cells via targeted nucleic acid aptamers, thereby achieving potent cancer cell killing while minimizing damage to healthy tissues. The core value of aptamer-drug conjugates (ApDCs) lies in striking a balance between “targeted delivery,” “high-efficiency killing,” and “precision and safety.”

Leveraging its extensive experience in targeted aptamer development and an integrated aptamer drug development platform (including aptamer synthesis, modification, drug conjugation, affinity detection, in vitro efficacy evaluation, and in vivo efficacy evaluation), TekBiotech provides comprehensive services ranging from preclinical study design and ApDC discovery to downstream detection and efficacy evaluation. TekBiotech focuses on overcoming key challenges in ApDC development, conjugation uniformity, payload optimization, and comprehensive characterization, to accelerate the development of drug candidates and advance them from the laboratory to clinical trials.

█ Aptamer-Drug Conjugate (ApDC) Development Services

TekBiotech offers a standardized ApDC development process. Clients need only provide target information (primarily disease targets), and TekBiotech’s scientists will design appropriate screening targets and strategies based on the target’s characteristics, with the aim of obtaining specific targeting aptamers suitable for downstream ApDC development and application. ApDC development services cover a full suite of services, including screening target design and production, aptamer screening, aptamer synthesis and modification, ApDC design and synthesis, affinity detection, in vitro efficacy evaluation, and in vivo efficacy evaluation in animals. To help clients optimize the efficacy and safety of the final product, the company specifically offers ApDC conjugation condition optimization services (including the selection of linkers, both cleavable and non-cleavable, optimization of conjugation groups or methods, and selection of small-molecule drugs or toxins, etc.), aimed at determining the most suitable conjugation process and scheme for a specific ApDC.

TekBiotech primarily focuses on covalent linker design (including both cleavable and non-cleavable ApDC linkers). Its conjugation strategies generally fall into the following categories:

(1) Enzyme-responsive linker-mediated coupling: Utilizing specific enzymes highly expressed in tumors or lysosomes to trigger drug release (primarily using dipeptide, tetrapeptide, and glycosidic linkers)

(2) Chemical-responsive linker-based conjugation: Utilizes differences in the physicochemical properties between the blood and the intracellular and extracellular environments (such as pH and redox potential) to trigger drug release (primarily forming imine bonds, carbonate bonds, disulfide bonds, etc.)

(3) Non-cleavable covalent coupling: The entire ApDC must be internalized by the cell and the target moiety completely “digested” before the drug is released (primarily forming thioether bonds, amide bonds, etc.)

The structural diagram of an aptamer-drug conjugate (ApDC) (illustrating one type of coupling) is as follows:

Figure 1: Structural Diagram of an Aptamer-Drug Conjugate (ApDC)

█ ApDC Characterization and Analysis Services

TekBiotech offers a comprehensive suite of analytical services that comply with industry standards, covering all stages from early-stage screening to process scale-up. We utilize a variety of detection methods, including HPLC, mass spectrometry (MS), MALDI-TOF mass spectrometry, flow cytometry, BLI/SPR, and animal model detection, to conduct evaluations and provide critical data for process optimization.

TekBiotech offers the following characterization and analytical services:

HPLC and Mass Spectrometry (MS) Analysis	MALDI-TOF Mass Spectrometry	BLI/SPR	Flow Cytometry	Detection in Animal Models
Detection of Purity and Molecular Weight	Detect that the linker, drug, and nucleic acid aptamer are correctly linked	Analysis of Targeted Binding at the Molecular Level	Analysis of Targeted Binding at the Cellular Level	In Vivo Efficacy Evaluation and Target Analysis

█ Advantages of the ApDC Discovery Service Platform


One-Stop Solution	Optimization of Customized Coupling Processes	Comprehensive Characterization and Analysis Evaluation	A Mature Supporting Downstream Detection Platform is in Place
A comprehensive service covering everything from solution design, aptamer discovery, and ApDC construction to in vivo and in vitro detection	Offers a variety of coupling methods and linkers	Including molecular-level analysis of ApDC, cellular-level analysis, and analysis using animal models	Molecular targeting detection, cellular targeting detection, In vivo targeting dectection, and Efficacy Evaluation